The Drugs That Could Slow Aging Are Already Here | Dr. Nir Barzilai

Why It Matters

Recognizing aging as a treatable condition could slash billions in healthcare spending while extending productive life, reshaping pharma pipelines and insurance models.

Key Takeaways

• Geroscience targets aging biology to delay multiple diseases simultaneously
• Existing drugs like metformin, GLP-1 agonists already extend healthspan
• Clinical data shows GLP-1 reduces hospitalizations by ~60% in elderly
• Regulatory acceptance of aging therapies could cut healthcare costs dramatically
• Personalized longevity plans require doctor supervision, not DIY supplement overload

Summary

The Longevity Technology Unlocked podcast features Dr. Nir Barzilai, a leading voice in geroscience, discussing how targeting the biology of aging can add years of healthy life. He outlines the field’s evolution from a fringe “wild‑west” to a rapidly maturing discipline poised for regulatory approval by 2026.

Barzilai explains the geroscience hypothesis: aging drives most chronic diseases, so intervening at the root can simultaneously blunt cardiovascular, renal, and cognitive decline. He cites existing agents—metformin, intermittent fasting, SGLT2 inhibitors, GLP‑1 agonists, mTOR inhibitors, and NAD⁺ precursors—that already show health‑span benefits in clinical trials.

A striking example he shares is a JAMA study where GLP‑1 therapy cut hospitalizations and death by roughly 60 % among patients with diabetes and heart‑failure with preserved ejection fraction, saving $30‑40 k per patient in ICU costs. Barzilai also references his centenarian research, noting that those who live past 100 tend to remain disease‑free until the final year, dramatically lowering end‑of‑life medical expenses.

If regulators and payers accept aging‑targeted drugs as standard care, the health system could shift from costly end‑stage interventions to preventive longevity medicine, creating economic upside for insurers, employers, and patients. The conversation underscores the need for personalized, physician‑guided longevity plans rather than unregulated supplement regimens.

Original Description

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: https://rechargehealthas.sjv.io/jRQyQ5

----------

Guests: Nir Barzilai

Director of the Institute for Aging Research at the Albert Einstein College of Medicine

LinkedIn: https://www.linkedin.com/in/nir-barzilai-7a86a7212/

Link to Nir's works: https://einsteinmed.edu/faculty/484/nir-barzilai, https://www.sciencedirect.com/author/7005711408/nir-barzilai

----------

What if aging itself is the biggest medical opportunity of the 21st century?

Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once.

Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics.

Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity.

The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model.

In this episode, you’ll learn:

- Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular disease

- How centenarians compress morbidity and remain healthy into extreme old age

- Why GLP-1 therapies reduced hospitalization and death by roughly 60% in one study

- Why Barzilai tracks proteomics and believes biomarkers will transform longevity medicine

- Which longevity interventions he personally uses, including metformin and Rejuvant

If you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

----------

00:00:00 - The Geroscience Pioneer

00:02:01 - Nir's Longevity Stack

00:05:19 - What Is Geroscience?

00:10:14 - Why Healthspan Saves Money

00:14:27 - Lessons From Centenarians

00:16:58 - Which Drugs Extend Healthspan?

00:23:13 - Who Should Take Metformin?

00:25:48 - GLP-1s And Aging

00:35:44 - The Biomarker Revolution

00:40:03 - What Comes Next?

00:42:35 - Why Nir Takes Rejuvant

00:45:28 - Supplement Risks Explained

00:47:37 - FDA And Longevity Regulation

00:56:42 - Rapid Fire Insights

00:58:32 - The Next Decade Of Aging Biotech